Código QR (código de barras bidimensional)

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials

BackgroundWe sought to examine the efficacy and safety of 2 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and ResultsWe performed a systematic review and meta‐analysis of randomized controlled trials comparing treatment with and without PCSK9 in...

ver descrição completa

Na minha lista:
Principais autores: Aris Karatasakis, Barbara A Danek, Judit Karacsonyi, Bavana V Rangan, Michele K Roesle, Thomas Knickelbine, Michael D Miedema, Houman Khalili, Zahid Ahmad, Shuaib Abdullah, Subhash Banerjee, Emmanouil S. Brilakis
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2017-12-01
coleção:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Assuntos:
alirocumab
evolocumab
hyperlipidemia
outcome
PCSK9
Acesso em linha:https://www.ahajournals.org/doi/10.1161/JAHA.117.006910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados